Entrada Therapeutics Files 8-K on Bylaws and Shareholder Votes

TL;DR

ENTX filed an 8-K covering bylaw changes and shareholder votes. Nothing major disclosed.

AI Summary

On June 13, 2024, Entrada Therapeutics, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, the submission of matters to a vote of security holders, and financial statements and exhibits. No specific financial figures or significant corporate actions beyond these procedural filings were detailed in the provided excerpt.

Why It Matters

This filing indicates routine corporate governance activities, including potential changes to bylaws and shareholder decisions, which are standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing appears to be procedural and does not disclose any new material risks or significant negative events.

Key Players & Entities

• Entrada Therapeutics, Inc. (company) — Registrant
• 0001104659-24-071249 (filing_id) — Accession Number
• June 13, 2024 (date) — Report Date
• Delaware (jurisdiction) — State of Incorporation
• 001-40969 (commission_file_number) — SEC File Number
• 813983399 (irs_number) — IRS Employer Identification No.
• Boston, MA (location) — Business Address City/State
• 02210 (zip_code) — Business Address Zip

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TRDA The Nasdaq

Filing Documents

• tm2417220d1_8k.htm (8-K) — 40KB
• tm2417220d1_ex3-1.htm (EX-3.1) — 12KB
• 0001104659-24-071249.txt ( ) — 230KB
• trda-20240613.xsd (EX-101.SCH) — 3KB
• trda-20240613_lab.xml (EX-101.LAB) — 33KB
• trda-20240613_pre.xml (EX-101.PRE) — 22KB
• tm2417220d1_8k_htm.xml (XML) — 4KB

03. Amendments to Articles of Incorporation or Bylaws; Change

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Years. On June 13, 2024, Entrada Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") in a virtual-only format via live webcast. As further described in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") to limit the liability of certain officers of the Company as permitted by Delaware law, as described in the Company's definitive proxy statement (the "Proxy Statement") filed on April 29, 2024 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The Certificate of Amendment was previously approved by the Company's Board of Directors (the "Board"), subject to approval by the Company's stockholders. On June 13, 2024, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective upon filing. The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. The Annual Meeting was held on June 13, 2024. Proxies were solicited pursuant to the Proxy Statement. As of the close of business on April 16, 2024, the record date for the Annual Meeting, the number of shares of the Company's common stock, $0.0001 par value per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting was 33,677,918. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 22,221,263, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Annual Meeting. At the Annual Meeting, the Company's stockholders were asked to vote on the following matters, which are described in detail in the Proxy Statement: (i) to elect one Class III director nominee to the Board, to serve until the Company's 2027 annual meeting of stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation or removal ("Proposal No. 1"), (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal No. 2"), and (iii) to approve the Certificate of Amendment to limit the liability of certain of the Company's officers as permitted by Delaware law ("Proposal No. 3"). The voting results reported below are final. Proposal No. 1 Gina Chapman was duly elected to the Board as a Class III director. The results of the stockholders' vote with respect to the election were as follows: CLASS III DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Gina Chapman 19,701,297 101,960 2,418,006 Proposal No. 2 The appointment of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: June 13, 2024 /s/ Dipal Doshi Dipal Doshi Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR